Different mechanisms define the antiadhesive function of high molecular weight kininogen in integrin- and urokinase receptor-dependent interactions

Blood

Volumn 96, Issue 2, 2000, Pages 514-522

  Chavakis, Triantafyllos ^b   Kanse, Sandip M ^b   Lupu, Florea ^b   Hammes, Hans Peter ^b   Müller Esterl, Werner ^b   Pixley, Robin A ^b   Colman, Robert W ^b   Preissner, Klaus T ^a  

^a JUSTUS LIEBIG UNIVERSITY   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

FIBRONECTIN; HEPARIN; INTEGRIN; KININOGEN; PLASMINOGEN ACTIVATOR INHIBITOR 1; UROKINASE; UROKINASE RECEPTOR; VITRONECTIN;

ARTICLE; CELL ADHESION; CELL INTERACTION; HUMAN; HUMAN CELL; INFLAMMATION; PRIORITY JOURNAL; PROTEIN DEGRADATION; RECEPTOR BINDING;

EID: 0034661540     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v96.2.514     Document Type: Article

References (68)

1. Pöllänen J, Stephens RW, Vaheri A. Directed plasminogen activation at the surface of normal and malignant cells. Adv Cancer Res. 1991;57: 273.
2. Lin CQ, Bissell MJ. Multi-faceted regulation of cell differentiation by extracellular matrix. FASEB J. 1993;7:737.
3. Carlos TM, Harlan JM. Leukocyte-endothelial adhesion molecules. Blood. 1994;84:2068.
4. Gailit J, Clark RAF. Wound repair in the context of extracellular matrix. Curr Opin Cell Biol. 1994;6: 717.
5. Preissner KT, Pötzsch B. Vessel wall-dependent metabolic pathways of the adhesive proteins, von-Willebrand-factor and vitronectin. Histol Histopathol. 1995;10:239.
6. Loridon-Rosa B, Vielh P, Cuadrado C, Burtin P. Comparative distribution of fibronectin and vitronectin in human breast and colon carcinomas. Am J Comp Pathol. 1988;90:7.
7. Casaroli Marano RP, Preissner KT, Vilaro S. Fibronectin, laminin, vitronectin and their receptors at newly-formed capillaries in proliferative diabetic retinopathy. Exp Eye Res. 1995;60:5.
8. Hammes HP, Weiss A, Hess S, et al. Modification of vitronectin by advanced glycation alters functional properties in vitro and in the diabetic retina. Lab Invest. 1996;75:325.
9. Brooks PC, Montgomery AM, Rosenfeld M, et al. Integrin αvβ3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell. 1994;79:1157.
10. Hammes HP, Brownlee M, Joncyk A, Sutter A, Preissner KT. Subcutaneous injection of a cyclic peptide antagonist of vitronectin receptor-type integrins inhibits retinal neo-vascularization. Nat Med, 1996;2:529.
11. Preissner KT, May AE, Wohn KD, Germer M, Kanse SM. Molecular crosstalk between adhesion receptors and proteolytic cascades in vascular remodeling. Thromb Haemost. 1997;78:88.
12. Chapman HA. Plasminogen activators, integrins, and the coordinated regulation of cell adhesion and migration. Curr Opin Cell Biol. 1997;9:714.
13. Waltz DA, Sailor LZ, Chapman HA. Cytokines induce urokinase-dependent adhesion of human myeloid cells: a regulatory role for plasminogen activator inhibitors. J Clin Invest. 1993;91:1541.
14. Waltz DA, Chapman HA. Reversible cellular adhesion to vitronectin linked to urokinase receptor occupancy. J Biol Chem. 1994;269:14746.
15. Waltz DA, Natkin LR, Fujita RM, Wei Y, Chapman HA. Plasmin and plasminogen activator inhibitor type I promote cellular motility by regulating the interaction between the urokinase receptor and vitronectin. J Clin Invest. 1997;100:58.
16. Kjoller L, Kanse SM, Kirkegaard T, et al. Plasminogen activator inhibitor-1 represses integrin-and vitronectin-mediated cell migration independently of its function as an inhibitor of plasminogen activation. Exp Cell Res. 1997;232:420.
17. Stefansson S, Lawrence DA. The serpin PAI-1 inhibits cell migration by blocking integrin αvβ3 binding to vitronectin. Nature. 1996;383:441.
18. Wei Y, Waltz DA, Rao N, Drummond RJ, Rosenberg S, Chapman HA. Identification of the urokinase receptor as an adhesion receptor for vitronectin. J Biol Chem. 1994;269:32380.
19. Kanse SM, Kost C, Wilhelm OG, Andreasen PA, Preissner KT. The urokinase receptor is a major vitronectin binding protein on endothelial cells. Exp Cell Res. 1996;224:344.
20. Colman RW, Pixley RA, Najamunnisa S, et al. Binding of high molecular weight kininogen to human endothelial cells is medited via a site within domains 2 and 3 of the urokinase receptor. J Clin Invest. 1997;100:1481.
21. Berrettini M, Schleef RR, Heeb MJ, Hopmeier P, Griffin JH. Assembly and expression of an intrinsic factor IX activator complex on the surface of cultured human endothelial cells. J Biol Chem. 1992;267:19833.
22. Tait JF, Fujikawa K. Identification of the binding site for plasma prekallikrein in human high molecular weight kininogen: a region from residues 185 to 224 of the kininogen light chain retains full binding activity. J Biol Chem. 1986;261:15396.
23. Tait JF, Fujikawa K. Primary structure requirements for the binding of human high molecular weight kininogen to plasma prekallikrein and factor XI. J Biol Chem. 1987;262:11651.
24. Nishikawa K, Shibayama Y, Kuna P, Calcaterra E, Kaplan AP, Reddigari SR. Generation of vasoactive peptide bradykinin from human umbilical vein endothelium-bound high molecular weight kininogen by plasma kallikrein. Blood. 1992;80: 1980.
25. Retzios AD, Rosenfeld R, Schiffman S. Effects of chemical modifications on the surface-and protein-binding properties of the light chain of human high molecular weight kininogen. J Biol Chem. 1987;262:3074.
26. Kunapuli SP, DeLa Cadena RA, Colman RW. Deletion mutagenesis of high molecular weight kininogen light chain: identification of two anionic surface binding subdomains. J Biol Chem. 1993; 268:2486.
27. Bjork I, Olson ST, Shelter RG, Shore JD. Binding of heparin to human high molecular weight kininogen. Biochemistry. 1989;28:1213.
28. DeLa Cadena RA, Colman RW. The sequence HGLGHGHEQQHGLGHGH in the light chain of high molecular weight kininogen serves as a primary structural feature for zinc-dependent binding to an anionic surface. Protein Sci. 1992;1:151.
29. Herwald H, Hasan AAK, Godovac-Zimmermann J, Schmaier AH, Müller-Esterl W. Identification of an endothelial cell binding site on kininogen domain D3. J Biol Chem. 1995;270:14634.
30. Hasan AAK, Cines DB, Herwald H, Schmaier AH, Müller-Esterl W. Mapping the cell binding site on high molecular weight kininogen domain 5. J Biol Chem. 1995;270:19256.
31. Lin Y, Harris RB, Yan W, McCrae KR, Zhang H, Colman RW. High molecular weight kininogen peptides inhibit the formation of kallikrein on endothelial cell surfaces and subsequent urokinase-dependent plasmin formation. Blood. 1997;90: 690.
32. Gustafson EJ, Lukasiewicz H, Wachtfogel YT, et al. High molecular weight kininogen inhibits fibrinogen binding to cytoadhesins of neutrophils and platelets. J Cell Biol. 1989;109:377.
33. Wachtfogel YT, DeLa Cadena RA, Kunapuli SP, et al. High molecular weight kininogen binds to Mac-1 on neutrophils by its heavy chain (domain 3) and its light chain (domain 5). J Biol Chem. 1994;269:19307.
34. Hasan AAK, Zisman T, Schmaler AH. Identification of cytokeratin 1 as a binding protein and presentation receptor for kininogens on endothelial cells. Proc Natl Acad Sci U S A. 1998;95:3615.
35. Herwald H, Dedio J, Kellner R, Loos M, Müller-Esterl W. Isolation and characterization of the kininogen-binding protein p33 from endothelial cells: identity with the gC1q receptor. J Biol Chem. 1996;271:13040.
36. Joseph K, Ghebrehiwet B, Peerschke EIB, Reid KBM, Kaplan AP. Identification of the zinc-dependent endothelial cell binding protein for high molecular weight kininogen and factor XII: identity with the receptor that binds to the globular "heads" of C1q (gC1qR). Proc Natl Acad Sci U S A. 1996;93:8552.
37. Dedio J, Jahnen-Dechent WJ, Bachmann M, Müller-Esterl W. The multiligand-binding protein gC1qR, putative C1q receptor, is a mitochondrial protein. J Immunol. 1998;160:3534.
38. Asakura S, Hurley RW, Skorstengaard K, Ohkubo I, Mosher DF. Inhibition of cell adhesion by high molecular weight kininogen. J Cell Biol. 1992;116: 465.
39. Asakura S, Yang W, Sottile J, et al. Opposing effects of low and high molecular weight kininogens on cell adhesion. J Biochem. 1998;124:473.
40. Nelles J, Lijnen HR, Collen D, Holmes WE. Characterization of recombinant human single-chain urokinase-type plasminogen activator mutants produced by site-specific mutagenesis of Lys158. J Biol Chem. 1987;262:5682.
41. Preissner KT, Wassmuth R, Müller-Berghaus G. Physicochemical characterization of human S-protein and its function in the blood coagulation system. Biochem J. 1985;231:349.
42. Stockmann A, Hess S, DeClerck P, Timpt R, Preissner KT. Multimeric vitronectin: identification and characterization of conformation-dependent self-association of the adhesive protein. J Biol Chem. 1993;268:22874.
43. Bradford HN, Jameson BA, Adam AA, Wassell RP, Colman RW. Contiguous binding and inhibitory sites on kininogens required for the inhibition of platelet calpain. J Biol Chem. 1993;268:26546.
44. Standker L, Enger A, Schulz-Knappe P, et al. Structural and functional characterization of vitronectin-derived RGD-containing peptides from human hemofiltrate. Eur J Biochem. 1996;241:557.
45. Kost C, Stüber W, Ehrlich H, Pannekoek H, Preissner KT. Mapping of binding sites for heparin, plasminogen activator inhibitor-1 and plasminogen to vitronectin's heparin binding region reveals a novel vitronectin-dependent feedback mechanism for the control of plasmin formation. J Biol Chem. 1992;267:12098.
46. Hoyer-Hansen G, Behrendt N, Ploug M, Dano K, Preissner KT. The intact urokinase receptor is required for efficient vitronectin binding: receptor cleavage prevents ligand interaction. FEBS Lett. 1997;420:79.
47. Kaufmann J, Haasemann M, Modrow S, Müller-Esterl W. Structural dissection of the multidomain kininogens: fine mapping of the target epitopes of antibodies interfering with their functional properties. J Biol Chem. 1993;268:9079.
48. Zink S, Rösen P, Lemoine H. Micro-and macrovascular endothelial cells in β-adrenergic regulation of transendothelial permeability. Am J Physiol. 1995;269:C1209.
49. Fraker PJ, Speck JC. Protein and cell membrane iodination with a sparingly soluble chloramide, 1,3,4,6-tetrachloro-3a,6a-diphenyl-glycoluril. Biochem Biophys Res Commun. 1978;80:849.
50. Preissner KT, Anders E, Grulich-Henn J, Müller-Berghaus G. Attachment of cultured human endothelial cells is promoted by specific association with S protein (vitronectin) as well as with the ternary S protein-thrombin-antithrombin III complex. Blood. 1988;71:1581.
51. Chavakis T, May AE, Preissner KT, Kanse SM. Molecular mechanisms of zinc-dependant leukocyte adhesion involving the urokinase receptor and β2-integrins. Blood. 1999;93:2976.
52. Slot JW, Geuze HJ. A new method of preparing gold probes for multiple-labeling cytochemistry. Eur J Cell Biol. 1985;38:87.
53. Brash JL, Scott CF, ten Hove P, Wojciechowski P, Colman RW. Mechanism of transient adsorption of fibrinoger from plasma to solid surfaces: role of the contact and fibrinolytic systems. Blood. 1988;71:932.
54. Bale MD, Wohlfahrt LA, Mosher DF, Tomasini B, Sutton RC. Identification of vitronectin as a major plasma protein adsorbed on polymer surfaces of different copolymer composition. Blood. 1989;74: 2698.
55. Li CZ, Gurewich V, Liu JN. Urokinase-type plasminogen activator-induced monocyte adhesion is modulated by kininogen, kallikrein, factor XII, and plasminogen. Exp Cell Res. 1996;226:239.
56. Seiffert D, Loskutoff DJ. Evidence that type-1 plasminogen activator inhibitor binds to the somatomedin-B domain of vitronectin. J Biol Chem. 1991;266:2824.
57. Motta G, Rojkjaer R, Hasan AAK, Cines DB, Schmaier AH. High molecular weight kininogen regulates prekallikrein assembly and activation on endothelial cells: a novel mechanism for contact activation. Blood. 1998;91:516.
58. Preissner KT, Seiffert D. Role of vitronectin and its receptors in haemostasis and vascular remodeling. Thromb Res. 1998;89:1.
59. Colman RW, Jameson BA, Lin Y, Johnson D, Mousa SA. Domain 5 of high molecular weight kininogen (kininostatin) down-regulates endothelial cell proliferation and migration and inhibits angiogenesis. Blood. 2000;95:543.
60. Humphries J, DeLa Cadena RA, Atkins TL, Colman RW, Gonias SL. Interaction of high molecular weight kininogen with plasminogen inhibits binding of plasminogen to cell surfaces. Fibrinolysis. 1994;8:245.
61. Chavakis T, Kanse SM, Yutzy B, Lijnen HR, Preissner KT. Vitronectin concentrates proteolytic activity on the cell surface and extracellular matrix by trapping soluble urokinase receptor-urokinase complexes. Blood. 1998;91:2305.
62. Bradford HN, DeLa Cadena RA, Kunapuli SP, Dong JF, Lopez JA, Colman RW. Human kininogens regulate thrombin binding to platelets through the glycoprotein Ib-IX-V complex. Blood. 1997;90:1508.
63. DeLa Cadena RA, Wyshock EG, Kunapuli SP, et al. Platelet thrombospondin interactions with human high and low molecular weight kininogens. Thromb Haemost. 1994;72:125.
64. Lim BL, Reid KBM, Ghebrehiwet B, Peerschke EIB, Leight LAE, Preissner KT. The binding protein for globular heads of complement C1q, gC1qR: functional expression and characterization as a novel vitronectin binding factor. J Biol Chem. 1996;271:26739.
65. Chhatwal GS, Preissner KT, Müller-Berghaus G, Blobel H. Specific binding of the human S protein (vitronectin) to streptococci, Staphylococcus aureus, and Escherichia coli. Infect Immun. 1987; 55:1878
66. Herwald H, Mörgelin M, Olson A, et al. Activation of the contact-phase system on bacterial surfaces: a clue to serious complications in infectious diseases. Nat Med. 1998;4:298.
67. Fay WP, Parker AC, Ansari MN, Zheng X, Ginsburg D. Vitronectin inhibits the thrombotic response to arterial injury in mice. Blood. 1999;93: 1825.
68. Colman RW, White JV, Scovell S, Stadnicki A, Sartor RB. Kininogens are antithrombotic proteins in vivo. ArteriosclerThromb Vasc Biol. 1999; 19:2245.